BR0014742A - Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent - Google Patents

Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent

Info

Publication number
BR0014742A
BR0014742A BR0014742-7A BR0014742A BR0014742A BR 0014742 A BR0014742 A BR 0014742A BR 0014742 A BR0014742 A BR 0014742A BR 0014742 A BR0014742 A BR 0014742A
Authority
BR
Brazil
Prior art keywords
cell
pro
agent
inflammatory
peripheral blood
Prior art date
Application number
BR0014742-7A
Other languages
Portuguese (pt)
Inventor
James A Clagett
Craig Palmer
Original Assignee
Histatek Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histatek Llc filed Critical Histatek Llc
Publication of BR0014742A publication Critical patent/BR0014742A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA A INIBIçãO DE UMA RESPOSTA PRó-INFLAMATóRIA DE UMA CéLULA MONONUCLEAR E CéLULA POLIMORFONUCLEAR DE SANGUE PERIFéRICO HUMANO, OU UMA CéLULA DE TECIDO FIXADO, QUANDO CONTACTADA COM UM AGENTE PRó-INFLAMATóRIO, COMPLEXO DE RECEPTOR, E, MéTODO PARA A IDENTIFICAçãO DE UM AGENTE DE MODIFICAçãO DE VIA DE SINAL DE PROTEìNA G QUINASE". Um método para a inibição de uma resposta pró-inflamatória e uma célula mononuclear de sangue periférico humano ou célula polimorfonuclear ou célula de tecido fixado é descrito. A célula é contada com um agente pró-inflamatório para estimular a resposta pró-inflamatória. Então, a célula é contactada com um agente de modificação de via de sinal de proteína G quinase, assim inibindo as vias de transdução de sinal de resposta inflamatória mediadas por proteína G. Um complexo de receptor é descrito em que um agente de modificação de via de sinal de proteína G quinase se liga a um receptor de superfície de célula de uma célula mononuclear e célula polimorfonuclear de sangue periférico humano que foi estimulada por um agente pró-inflamatório."METHOD FOR THE INHIBITION OF A PRO-INFLAMMATORY RESPONSE TO A MONUMENTAL CELL AND HUMAN PERIPHERAL BLOOD POLYMORPHONUCLEAR CELL, OR A FIXED TISSUE CELL, WHEN CONTACTED WITH A PRO-INFLAMMATORY, COMPLEX, AGENT AND COMPETENT AGENT AN AGENT OF MODIFICATION OF THE PROTEIN G KINASE SIGNAL ROUTE ". A method for inhibiting a pro-inflammatory response and a human peripheral blood mononuclear cell or polymorphonuclear cell or fixed tissue cell is described. The cell is relied on a pro-inflammatory agent to stimulate the pro-inflammatory response. Then, the cell is contacted with a protein G kinase signal pathway modifying agent, thereby inhibiting G protein-mediated inflammatory response signal transduction pathways. A receptor complex is described in which a pathway modifying agent of protein G kinase signal binds to a cell surface receptor of a mononuclear cell and a human peripheral blood polymorphonuclear cell that has been stimulated by a pro-inflammatory agent.

BR0014742-7A 1999-10-15 2000-10-12 Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent BR0014742A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15967799P 1999-10-15 1999-10-15
PCT/US2000/028183 WO2001029069A1 (en) 1999-10-15 2000-10-12 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent

Publications (1)

Publication Number Publication Date
BR0014742A true BR0014742A (en) 2002-08-27

Family

ID=22573520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014742-7A BR0014742A (en) 1999-10-15 2000-10-12 Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent

Country Status (16)

Country Link
EP (1) EP1222199A4 (en)
JP (1) JP2004507441A (en)
KR (1) KR20020057972A (en)
CN (1) CN100497374C (en)
AU (1) AU8014200A (en)
BR (1) BR0014742A (en)
CA (1) CA2387559A1 (en)
CZ (1) CZ20021342A3 (en)
EA (1) EA200200451A1 (en)
HU (1) HUP0203688A2 (en)
IL (1) IL149125A0 (en)
MX (1) MXPA02003782A (en)
NO (1) NO20021732L (en)
PL (1) PL356096A1 (en)
WO (1) WO2001029069A1 (en)
ZA (1) ZA200202937B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20070116687A1 (en) * 2003-05-13 2007-05-24 Medvet Science Pty, Ltd. Method of modulating cellular transmigration and agents for use therein
KR20080033331A (en) 2005-07-05 2008-04-16 바이오템프트, 비.브이. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US20110082091A1 (en) * 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037651B1 (en) * 1997-11-13 2009-05-27 Mowycal Lending, LLC Small peptides and methods for treatment of asthma and inflammation

Also Published As

Publication number Publication date
PL356096A1 (en) 2004-06-14
HUP0203688A2 (en) 2003-02-28
JP2004507441A (en) 2004-03-11
ZA200202937B (en) 2003-09-23
CA2387559A1 (en) 2001-04-26
AU8014200A (en) 2001-04-30
WO2001029069A1 (en) 2001-04-26
CN1633447A (en) 2005-06-29
MXPA02003782A (en) 2002-12-13
KR20020057972A (en) 2002-07-12
IL149125A0 (en) 2002-11-10
NO20021732D0 (en) 2002-04-12
NO20021732L (en) 2002-06-12
CZ20021342A3 (en) 2003-01-15
CN100497374C (en) 2009-06-10
EA200200451A1 (en) 2002-10-31
EP1222199A4 (en) 2003-03-12
EP1222199A1 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
Wadenberg et al. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?
BR0014742A (en) Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent
Teitelbaum The epidermal growth factor receptor is coupled to a phospholipase A2-specific pertussis toxin-inhibitable guanine nucleotide-binding regulatory protein in cultured rat inner medullary collecting tubule cells.
BR9913887A (en) Compound, and, methods of inhibiting protein kinase activity, treating a patient who has a condition that is mediated by protein kinase activity and decreasing fertility in a patient
BR0213846A (en) methods of selectively inducing apoptosis in dr5-expressing target cells, inhibiting proliferation of dr5-expressing target cells, and treating a patient having an inflammatory disease or autoimmune disease;
TR199800759T2 (en) Protein Kinase C Inhibitor.
BR0114754A (en) Non-Imidazole Compounds
BR0016126A (en) Total or partial a1 agonists substituted adenosine-substituted 5'-unio heterocyclic derivatives
BRPI0411295A (en) compounds and their use in therapy
BR0015821A (en) Pyrimidine derivatives
WO2000006728A3 (en) Phosphorylation effectors
EE200100243A (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
Schwarz et al. Functional coupling of nitric oxide synthase and soluble guanylyl cyclase in controlling catecholamine secretion from bovine chromaffin cells
BRPI0518795A2 (en) Methods for determining the effectiveness of an individual's anti-inflammatory therapeutic treatment and for selecting an individual suffering from a certain inflammatory disease to receive anti-inflammatory therapeutic treatment
BR0015540A (en) Adenosine receptor antagonists and methods of preparing and using them
NO20001515L (en) Vitronectin receptor antagonist
Platts et al. Microtubule-dependent regulation of vasomotor tone requires Rho-kinase
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
NO983860L (en) Novel triazolopurins, their method of preparation and their use as drugs
ITFI990094A0 (en) DIAGNOSTIC METHOD FOR THE RECOGNITION OF HUMAN NEOPLASIES THROUGH THE DETERMINATION OF THE CTN-C ISOFORM OF TN-C, FRAGMENTS OF
BR9814867A (en) Method for treating disease-related or drug-induced dyskinesias
BR9812531A (en) Combination of components, pharmaceutical preparation, production thereof, and use of the combination or pharmaceutical preparation
Mehta et al. Relationship between paxillin and myosin phosphorylation during muscarinic stimulation of smooth muscle
BR9812404A (en) Combination of an endothelin antagonist, pharmaceutical preparation, process for preparing a pharmaceutical preparation, and use of a combination of a beta receptor blocker and an endothelin antagonist
ATE277639T1 (en) COMPOSITIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.